Tryp Therapeutics Inc. is a biopharmaceutical company dedicated to identifying and advancing novel therapeutic compounds for medical conditions characterized by significant unmet needs. Its flagship development initiative, known as PFN, focuses on addressing neuropsychiatric disorders by utilizing precisely formulated synthetic psilocybin. Within the PFN framework, specific drug candidates TRP-8802 and TRP-8803 are being developed to potentially treat a range of complex conditions, including fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity.